Mpox Treatment Market: Current Analysis and Forecast (2024-2032)

Mpox or formerly known as monkeypox is an infectious viral disease which is caused by monkeypox virus, a type of virus of Orthopoxvirus. This disease manifests symptoms as smallpox and causes fever and swollen lymph nodes with flat skin lesions that develop into ulcerated blisters filled with pus, which later crust over. Signs and symptoms usually develop between 1 to 21 days after potential exposure and generally range between two to four weeks. This rash starts in the face and may extend to other parts of the body such as the palms of the hands and soles of the feet. Transmission is through contact with infected persons or animals, contaminated objects, or direct aerosol droplets. In most cases, the signs are relatively mild and go away on their own, but sometimes there could be severe complications in special groups of patients, for example, children and immunocompromised patients. There is a vaccine available, as a preventive measure that is advised for combating this infectious disease.

The Mpox Treatment Market is expected to grow with a significant CAGR of 10.86% during the forecast period (2024-2032). This is mainly due to the continuous research and development by pharmaceutical companies, along with increased mergers and acquisitions activities to boost their capacities and shares to increase their knowledge of new advancements and technologies, which can enhance the development of therapeutics for mpox. Moreover, the increasing incidence of mpox has acted as a catalyst for increased government support and funding to accelerate the therapeutic development process. For instance, in September 2024, UNICEF signed an agreement that secures supply of the MVA-BN mpox vaccine at the lowest market price and ensures access to the vaccine for 77 low- and lower-middle-income countries. This agreement is an effort to meet the demand for more affordable vaccines.

Depending on the treatment type the market is divided into two categories namely prophylactic and therapeutic. Because of early intervention, the prophylactic treatment type segment emerges as the largest in the year 2023. The use of preventive measures and especially the use of vaccines are essential in preventing the spread of mpox virus. JYNNEOS and Imvanex are some vaccines that are used to prevent infections, especially during the period of the outbreak. Besides, governments and health organizations are inclining more towards vaccination drives in order to prevent mpox outbreaks hence contributing to a high growth rate of the prophylactic segment. In the therapeutic segment, there are three therapeutics available in the mpox treatment market, these are tecovirimat, brincidofovir, and cidofovir. The tecovirimat therapeutic is the most widely used and only approved therapeutics in the mpox treatment market. It is the first-line therapeutic treatment recommended by the U.S. Food and Drug Administration (FDA) for Mpox. However, brincidofovir and cidofovir are used in other viral infections primarily and their role in mpox treatment is not quite clear therefore they are not widely used in this market.

Based on the route of administration, the market is segmented into oral and injectable segments. The injectable segment holds the maximum share of the global Mpox treatment Market. Injectable medications, such as tecovirimat and cidofovir, provide faster therapeutic effects than oral formulations. This is very important in controlling diseases like mpox that present acute infection and call for early action on the patients. These formulations do not pass through the gastrointestinal feed, hence giving full bioavailability as well as plasma concentration levels. The efficacy of oral medications may be further compromised by changes in absorption caused by food interference or gastrointestinal illnesses. However, the growing preference by clinicians and patients for oral therapies boosts this market as the majority of the patients prefer easy-to-swallow therapies.

According to the distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, Community Health Centers, and online. In these segments, the hospital pharmacy has taken the largest market share owing to the usage of better therapeutics and vaccines available for mpox treatment. Hospital pharmacies promote integrated care by enabling caregivers to synchronize patient care with other health services. It is also important when assessing patients' outcomes and performing follow-ups that may include complications that are related to mpox. Additionally, the Community Health Centers as a distribution channel is expected to offer great potential in improving Mpox treatment access to the people living in areas where hospitals are not accessible. These centers produce better patient outcomes by reaching patients in large numbers.

For a better understanding of the market adoption of mpox treatment options such as vaccines and therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The Asia-Pacific region is anticipated to grow with a considerable CAGR in the forecast period of 2024-2032 due to the rising incidence of mpox in the population, predominantly in China and India. It is to be emphasized on creating the necessary measures for containing mpox through the promotion of prevention measures including vaccines and with promoting research and development in mpox treatment market within the Asia-Pacific region. For instance, on August 2024, Bavarian Nordic A/S announced that Singapore's medicines regulatory authority, Health Sciences Authority (HSA), has approved JYNNEOS(R) (MVA-BN) for prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection.

Some of the major players operating in the market include Bavarian Nordic A/S, SIGA Technologies, Inc., Tonix Pharmaceuticals Holding Corp., BioNTech SE., Emergent BioSolutions Inc., GeoVax Labs, Inc., Gilead Sciences, Inc., KM Biologics Co., Ltd., Moderna, Coalition for Epidemic Preparedness Innovations ("CEPI").